Hazardous Alcohol Use and Its Effect on Direct-Acting Antiviral Therapy Initiation among People with Active Injection Drug Use and Current Hepatitis C Infection
Author:
Karimi-Sari Hamidreza1ORCID, Lucas Gregory M.1ORCID, Zook Katie1, Weir Brian2, Landry Miles1, Sherman Susan G.2, Page Kathleen R.1ORCID, Falade-Nwulia Oluwaseun1
Affiliation:
1. Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA 2. Department of Health, Behavior and Society, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD 21205, USA
Abstract
Background: Hepatitis C virus (HCV) infection and hazardous alcohol use are both preventable causes of morbidity and mortality among people who inject drugs (PWID). In the general population, hazardous alcohol is associated with a reduced likelihood of HCV treatment initiation. Less is known about the prevalence and impact of hazardous alcohol use on direct-acting antiviral (DAA) therapy initiation among PWID with active injection drug use. Methods: PWID were recruited via street outreach in Baltimore, Maryland, between 2018 and 2019 and were enrolled in a study cohort. Participants completed a study survey and underwent HCV testing. Self-reported DAA therapy initiation was evaluated at follow-up visits every six months. Hazardous alcohol use was determined based on an AUDIT-C score of ≥4 for men or ≥3 for women. Data were analyzed using multivariable logistic regression with generalized estimating equations. Results: Of the 720 PWID recruited, 291 had detectable HCV RNA, and only 134 were aware of their HCV infection. The mean (±standard deviation) age of those that were aware of their infection was 48.7 (±10.3) years, with a slight majority (53.0%) being male and predominantly African American (64.9%). The majority (80/134, 59.7%) met criteria for hazardous alcohol use. Only 16 (11.9%) PWID reported DAA therapy initiation within six months, and 20 (14.9%) reported it within 12 months of follow-up. Hazardous alcohol use (aOR = 1.23, 95% CI = 0.43–3.53) was not associated with DAA treatment initiation. Conclusions: There was a high prevalence of hazardous alcohol use, low rates of oral DAA therapy initiation, and no association between self-reported hazardous alcohol use and initiation of oral DAA therapy in our sample of PWID that were aware of their chronic HCV infection. Strategies to increase HCV treatment uptake in PWID with active drug use are urgently needed and should integrate alcohol and drug use evaluation and care.
Funder
National Institute on Drug Abuse National Institutes of Health and the Johns Hopkins Center for AIDS Research
Reference29 articles.
1. High levels of all-cause mortality among people who inject drugs from 2018 to 2022;Roussos;Int. J. Drug Policy,2024 2. Hall, E.W., Bradley, H., Barker, L.K., Lewis, K.C., Shealey, J., Valverde, E., Sullivan, P., Gupta, N., and Hofmeister, M.G. (2024). Estimating hepatitis C prevalence in the United States, 2017–2020. Hepatology, Online ahead of print. 3. Epidemiology of injecting drug use, prevalence of injecting-related harm, and exposure to behavioural and environmental risks among people who inject drugs: A systematic review;Degenhardt;Lancet Glob. Health,2023 4. Centers for Disease Control and Prevention (CDC) (2024, July 01). Hepatitis C Surveillance 2021. August 2023, Available online: https://www.cdc.gov/hepatitis/statistics/2021surveillance/hepatitis-c.htm. 5. Risk factors for hepatocellular carcinoma in treated chronic hepatitis C patients-Relationship to smoking and alcohol;Matsuura;JGH Open,2020
|
|